Filing Details

Accession Number:
0000899243-19-002316
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-02-01 16:30:45
Reporting Period:
2019-01-31
Accepted Time:
2019-02-01 16:30:45
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1521036 Lantheus Holdings Inc. LNTH In Vitro & In Vivo Diagnostic Substances (2835) 352318913
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1610664 Cesare Orlandi C/O Lantheus Holdings, Inc.
331 Treble Cove Road
North Billerica MA 01862
Chief Medical Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2019-01-31 3,060 $16.56 77,746 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
Footnotes
  1. Starting in 2019, the Company requires certain senior executives to cover tax liabilities resulting from the vesting of their equity awards pursuant to sell-to-cover transactions under 10b5-1 plans. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2018, to satisfy withholding tax liabilities of the Reporting Person associated with the vesting of restricted stock previously granted and reported on a previously filed Form 4.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.31 to $16.82, inclusive. The reporting person undertakes to provide to Lantheus Holdings, Inc., ("LNTH") any security holder of LNTH or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.